Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

H. pylori-eradication therapy improves insulin sensitivity, hepatic steatosis in NAFLD

13 Jan 2020

Helicobacter pylori-eradication therapy (HPET) in patients with nonalcoholic fatty liver disease (NAFLD) leads to greater improvement in homeostasis model assessment-insulin resistance (HOMA-IR) but exerts comparable effects on hepatic steatosis and liver enzymes as compared with diet and exercise alone, a study has shown.

The trial included 80 NAFLD patients with H. pylori coinfection, 36 of which were assigned to receive standard management therapy (SMT; diet and exercise) and 44 to HPET (SMT plus amoxicillin, clarithromycin and pantoprazole).

A total of 28 patients in the SMT group and 36 in the HPET group were included in a modified intention-to-treat population. At week 24, controlled attenuation parameter (CAP) scores significantly decreased in the two groups (p=0.002 and p<0.001, respectively), without significant between-group difference (p=0.213).

H. pylori infection was successfully eradicated in 68 percent of patients in the HPET group. This group of patients showed greater improvement in HOMA-IR at week 24 compared to nonresponders or those treated with SMT (p=0.007).

There were also significant reductions observed in liver enzymes in both groups, although the changes between them were similar. Meanwhile, lipid parameters remained stable at week 24 . The HPET group exhibited a significant increase in the levels of reduced glutathione, but the change was not statistically different relative to the SMT group.

More studies involving a larger sample size, more effective HPET regimen and paired liver biopsy are needed for improved understanding, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.